Dessauvagie Benjamin F, Zhao Wenying, Heel-Miller Kathryn A, Harvey Jennet, Bentel Jacqueline M
Department of Anatomical Pathology, Royal Perth Hospital, Perth, Western Australia, 6000, Australia.
Hum Pathol. 2007 Feb;38(2):284-92. doi: 10.1016/j.humpath.2006.08.003. Epub 2006 Nov 3.
Columnar cell lesions of the breast are detected with increasing frequency in routine pathology practice, in part as a result of the widespread biopsy of nonpalpable breast abnormalities detected by screening mammography. Immunohistochemical investigation of the lesions in relation to the normal breast or to other breast pathologies is not well characterized, and the malignant potential of this spectrum of lesions has not been examined clinically. In this study, a cohort of 45 breast specimens containing columnar cell lesions, in particular, columnar alteration of lobules with prominent apical snouts and secretions (CAPSS), was investigated for expression of a series of breast tumor biomarkers. Using a semiquantitative immunohistochemical scoring system, up-regulation of estrogen, progesterone, and androgen receptors in CAPSS lesions to levels not significantly different from that in in situ or invasive breast tumors was identified. In four cases where CAPSS within a specimen lacked expression of a steroid hormone receptor, the coexisting in situ or invasive carcinoma also lacked expression of that receptor. In 81% of CAPSS lesions, E-cadherin immunostaining was reduced in isolated foci of cells or was decreased in intensity in all cells within the lesion. Quantitation of Ki-67 immunostaining demonstrated that proliferation of cells within CAPSS lesions was increased, compared with normal breast epithelium, but was lower than that detected in in situ or invasive cancers within the same specimens. Results of these analyses indicate that CAPSS shares immunophenotypic alterations with other premalignant lesions, the clinical implications of which may be investigated using established breast tumor biomarkers.
在常规病理学实践中,乳腺柱状细胞病变的检出频率日益增加,部分原因是通过乳腺钼靶筛查发现的不可触及乳腺异常进行广泛活检所致。关于这些病变与正常乳腺或其他乳腺病理情况相关的免疫组织化学研究尚不充分,且这一系列病变的恶性潜能尚未进行临床研究。在本研究中,对45例含有柱状细胞病变的乳腺标本进行了研究,特别是具有显著顶端突起和分泌物的小叶柱状改变(CAPSS),检测了一系列乳腺肿瘤生物标志物的表达情况。使用半定量免疫组织化学评分系统,发现CAPSS病变中雌激素、孕激素和雄激素受体上调至与原位或浸润性乳腺癌无显著差异的水平。在4例标本中CAPSS缺乏类固醇激素受体表达的病例中,同时存在的原位癌或浸润癌也缺乏该受体的表达。在81%的CAPSS病变中,E-钙黏蛋白免疫染色在孤立的细胞灶中减少,或病变内所有细胞的强度降低。Ki-67免疫染色定量显示,与正常乳腺上皮相比,CAPSS病变内细胞增殖增加,但低于同一标本中原位癌或浸润癌的增殖水平。这些分析结果表明,CAPSS与其他癌前病变具有共同的免疫表型改变,其临床意义可利用已确立的乳腺肿瘤生物标志物进行研究。